Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for ...

As a treatment administered only once, it carries an enormous $2.2 million list price. Vertex and CRISPR Therapeutics haven't started recording significant sales of Casgevy yet, but it could start ...

The deal has been announced just a few days after the FDA lifted a clinical hold on a phase 1/2 trial of VX-880 – a stem cell therapy Vertex acquired through its near $1 billion acquisition of ...

Get prepared with the key expectations. Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

A second T1D program, VX-264, is in a phase 1/2 study. In the meantime, Vertex enjoys a monopoly in treating the underlying cause of CF. Newly approved Alyftrek will likely become the company's ...

Nintendo Switch 2 is finally confirmed. After literal years of unverified rumors, dubious leaks and copious amounts of online speculation, Nintendo has lifted the lid on its next-generation ...

UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals ... but sales still amounted to a whopping $12.2 billion. Pharmacy benefit managers were afraid not to cover the ...